Figure 5.

Impact of MEK inhibition on the RAS signature across 10 lung cancer cell lines. The Y-axis shows the RAS signature score in drug treated cell lines relative to vehicle treated controls.

Loboda et al. BMC Medical Genomics 2010 3:26   doi:10.1186/1755-8794-3-26
Download authors' original image